학술논문

Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomised, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma